Arovella Therapeutics Limited

ASX:ALA Stok Raporu

Piyasa değeri: AU$197.6m

Arovella Therapeutics Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Arovella Therapeutics's earnings have been declining at an average annual rate of -5.4%, while the Pharmaceuticals industry saw earnings growing at 35.4% annually. Revenues have been growing at an average rate of 15.8% per year.

Anahtar bilgiler

-5.4%

Kazanç büyüme oranı

49.8%

EPS büyüme oranı

Pharmaceuticals Sektör Büyümesi31.2%
Gelir büyüme oranı15.8%
Özkaynak getirisi-77.9%
Net Marj-448.0%
Son Kazanç Güncellemesi30 Jun 2024

Yakın geçmiş performans güncellemeleri

Recent updates

We're Hopeful That Suda Pharmaceuticals (ASX:SUD) Will Use Its Cash Wisely

Jul 01
We're Hopeful That Suda Pharmaceuticals (ASX:SUD) Will Use Its Cash Wisely

Gelir ve Gider Dağılımı

Arovella Therapeutics nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.


Kazanç ve Gelir Geçmişi

ASX:ALA Gelir, gider ve kazançlar (AUD Millions )
TarihGelirKazançlarG+A GiderleriAr-Ge Giderleri
30 Jun 242-927
31 Mar 242-936
31 Dec 232-1036
30 Sep 232-1035
30 Jun 231-1024
31 Mar 232-924
31 Dec 222-924
30 Sep 221-923
30 Jun 220-923
31 Mar 220-822
31 Dec 211-721
30 Sep 211-621
30 Jun 211-511
31 Mar 211-510
31 Dec 201210
30 Sep 201-110
30 Jun 201-410
31 Mar 201-1220
31 Dec 191-1510
30 Sep 191-1110
30 Jun 191-810
31 Mar 191-610
31 Dec 181-520
30 Sep 181-520
30 Jun 180-620
31 Mar 185-420
31 Dec 171-320
30 Sep 171-220
30 Jun 171-110
31 Mar 174-120
31 Dec 163-120
30 Sep 165-220
30 Jun 166-230
31 Mar 166-320
31 Dec 156-320
30 Sep 156-320
30 Jun 156-330
31 Mar 156-430
31 Dec 146-430
30 Sep 147-330
30 Jun 149-220
31 Mar 148-220
31 Dec 138-120

Kaliteli Kazançlar: ALA is currently unprofitable.

Büyüyen Kar Marjı: ALA is currently unprofitable.


Serbest Nakit Akışı ve Kazanç Analizi


Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: ALA is unprofitable, and losses have increased over the past 5 years at a rate of 5.4% per year.

Büyüme Hızlandırma: Unable to compare ALA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Kazançlar vs. Sektör: ALA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (46.5%).


Özkaynak Getirisi

Yüksek ROE: ALA has a negative Return on Equity (-77.89%), as it is currently unprofitable.


Varlık Getirisi


Kullanılan Sermaye Getirisi


Geçmişte güçlü performans gösteren şirketleri keşfedin